Clearside Biomedical, Inc. (CLSD) Financials
Newest figures come from the 10-Q for Q3 FY2025, filed Nov 14, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLSD SEC filings page.
Clearside Biomedical, Inc. (CLSD) reported $3.3M in revenue over the twelve months to Sep 30, 2025, down 56.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
This development-stage business spends far more on research than it earns, leaving financing—not revenue—to support operations.
In FY2024, research and development consumed$18.6M against revenue of just$1.7M , while operating cash flow was-$24.7M . That combination means reported sales are not yet funding the development effort; the business remains financed primarily through capital raised rather than internally generated cash.
The balance sheet has shifted from positive to negative equity: liabilities reached
Cash consumption is overwhelmingly operational rather than investment-driven. FY2024 free cash flow was
Financial Health Signals
Scored against emerging companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Clearside Biomedical, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Clearside Biomedical, Inc., and counted as zero in the overall score.
Clearside Biomedical, Inc. had 5M shares outstanding at the end of fiscal year 2024, against 63M in fiscal year 2023. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Clearside Biomedical, Inc. scores 96/100 among other emerging companies.
Clearside Biomedical, Inc. spent $18.6M on research and development in fiscal year 2024, which was 60.9% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Clearside Biomedical, Inc. scores 84/100 among other emerging companies.
Clearside Biomedical, Inc. reported revenue of $1.7M in fiscal year 2024, against $8.2M in fiscal year 2023. Revenue Progress ranks emerging companies on the three-year path of that line, and Clearside Biomedical, Inc. scores 58/100 among other emerging companies.
Clearside Biomedical, Inc.'s operations used $24.7M of cash in fiscal year 2024, against $18.1M used in fiscal year 2023. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Clearside Biomedical, Inc. scores 21/100 among other emerging companies.
Not available for Clearside Biomedical, Inc., and counted as zero in the overall score.
Clearside Biomedical, Inc. scores -22.72, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.1M) relative to total liabilities ($64.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Clearside Biomedical, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Clearside Biomedical, Inc. reported a net loss of $34.4M while operations used $24.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Clearside Biomedical, Inc. generated $201K in revenue in Q3 2025. This represents a decrease of 80.6% from the same quarter a year earlier. Against the prior quarter it is down 59.1%.
Clearside Biomedical, Inc. reported -$6.0M in net income in Q3 2025. This represents an increase of 22.3% from the same quarter a year earlier. Against the prior quarter it is down 32.9%.
Clearside Biomedical, Inc. earned -$1.14 per diluted share (EPS) in Q3 2025. This represents an increase of 26.0% from the same quarter a year earlier.
Not reported for Q3 2025.
Cash & Balance Sheet
Clearside Biomedical, Inc. recorded an outflow of $5.5M in free cash flow in Q3 2025, representing a cash shortfall after capex. This represents an increase of 8.1% from the same quarter a year earlier. Against the prior quarter it is down 15.9%.
Clearside Biomedical, Inc. held $6.8M in cash as of Q3 2025; long-term debt is not reported for that period.
Not reported for Q3 2025.
Margins & Returns
Clearside Biomedical, Inc.'s gross margin was 100.0% in Q3 2025, indicating the percentage of revenue retained after direct costs. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.
Not shown for Q3 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2025.
Capital Allocation
Clearside Biomedical, Inc. invested $2.9M in research and development in Q3 2025. This represents a decrease of 28.9% from the same quarter a year earlier. Against the prior quarter it is up 85.2%.
Clearside Biomedical, Inc. reported no capital expenditure in Q3 2025. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q3 2025.
CLSD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'25 | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $201K-80.6% | $492K+446.7% | $2.3M+913.0% | $306K-95.2% | $1.0M+20.8% | $90K-91.2% | $230K+5650.0% | $6.3M+1822.7% |
| Cost of Revenue | $0 | $0 | $248K | $149K | $0-100.0% | $0-100.0% | $0 | N/A |
| Gross Profit | $201K-80.6% | $492K+446.7% | $2.1M+805.2% | $157K | $1.0M+44.8% | $90K-88.8% | $230K | N/A |
| R&D Expenses | $2.9M-28.9% | $1.6M-65.6% | $4.5M-20.5% | $4.2M-32.8% | $4.1M-19.6% | $4.6M-7.0% | $5.6M+26.2% | $6.3M+25.6% |
| SG&A Expenses | $4.3M+51.5% | $2.5M-19.5% | $2.8M0.0% | $3.1M+3.9% | $2.8M+7.8% | $3.1M-1.6% | $2.8M-10.6% | $2.9M-7.0% |
| Operating Income | -$7.0M-18.6% | -$3.6M+53.0% | -$5.2M+36.6% | -$7.1M-145.2% | -$5.9M+15.9% | -$7.6M-4.4% | -$8.2M-7.9% | -$2.9M+63.9% |
| EBITDA | N/A | N/A | -$5.1M+37.4% | N/A | N/A | N/A | -$8.2M-7.8% | N/A |
| Income Tax | $0 | $0 | $715K | N/A | $0 | $0 | $0 | N/A |
| Net Income | -$6.0M+22.3% | -$4.5M+40.8% | -$8.2M+30.1% | -$7.3M-51.2% | -$7.7M+17.0% | -$7.6M+16.6% | -$11.8M-26.8% | -$4.8M+50.0% |
| EPS (Basic) | -$1.14+26.0% | -$0.06+40.0% | -$0.11+35.3% | N/A | -$1.54-926.7% | -$0.10+33.3% | -$0.17-13.3% | N/A |
| EPS (Diluted) | -$1.14+26.0% | -$0.06+40.0% | -$0.11+35.3% | N/A | -$1.54 | -$0.10+33.3% | -$0.17-13.3% | N/A |
| Diluted Shares (Avg) | 5M+5.0% | 78M+4.2% | 77M+10.1% | N/A | 5M | 75M+21.2% | 70M+14.2% | N/A |
Not reported in any period shown, so not listed: Interest Expense.
CLSD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'25 | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.6M-60.1% | $15.3M-54.8% | $19.7M-51.0% | $25.1M-26.1% | $29.2M-15.3% | $33.9M-13.4% | $40.1M-10.2% | $34.0M-33.7% |
| Current Assets | $8.3M-67.1% | $11.8M-60.4% | $16.0M-55.8% | $21.3M-29.4% | $25.1M-18.5% | $29.8M-17.6% | $36.1M-15.2% | $30.1M-39.0% |
| Cash & Equivalents | $6.8M-51.0% | $9.4M-48.6% | $13.6M-61.5% | $20.0M-30.8% | $13.9M-51.8% | $18.2M-47.9% | $35.4M-14.6% | $28.9M-40.1% |
| Accounts Receivable | $266K-66.2% | $816K | $1.5M | $507K+8.6% | $788K-10.7% | $0-100.0% | $0 | $467K |
| Total Liabilities | $65.6M+2.6% | $64.1M+3.0% | $65.6M+5.9% | $64.0M+28.1% | $64.0M+35.3% | $62.2M+40.9% | $62.0M+47.5% | $49.9M+22.7% |
| Current Liabilities | $2.8M-50.5% | $3.0M-48.1% | $5.0M-15.8% | $4.8M-29.6% | $5.6M-4.1% | $5.9M+11.4% | $6.0M+19.4% | $6.8M+17.8% |
| Non-Current Liabilities | $62.8M+7.6% | $61.0M+8.3% | $60.6M+8.1% | $59.2M+37.3% | $58.4M+40.8% | $56.3M+44.9% | $56.0M+51.3% | $43.1M+23.5% |
| Total Equity | -$54.0M-55.1% | -$48.7M-72.3% | -$45.9M-110.5% | -$38.9M-144.2% | -$34.8M-170.8% | -$28.3M-468.8% | -$21.8M-907.8% | -$15.9M-250.0% |
| Retained Earnings | -$374.0M-7.5% | -$368.0M-8.1% | -$363.5M-9.3% | -$355.3M-10.7% | -$348.0M-10.1% | -$340.3M-10.9% | -$332.7M-11.7% | -$320.9M-11.3% |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill, Long-Term Debt.
CLSD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'25 | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.5M+7.3% | -$4.7M+16.7% | -$5.8M+25.7% | -$5.3M-1161.4% | -$5.9M+2.7% | -$5.7M-6.4% | -$7.9M-8.8% | $495K+108.8% |
| Depreciation & Amortization | N/A | N/A | $85K+203.6% | N/A | N/A | N/A | $28K+86.7% | N/A |
| Stock-Based Compensation | N/A | N/A | $721K-32.1% | N/A | N/A | N/A | $1.1M+2.0% | N/A |
| Capital Expenditures | $0-100.0% | $0-100.0% | $9K-84.2% | $444K+270.0% | $53K-88.1% | $423K-61.4% | $57K-50.4% | $120K+31.9% |
| Free Cash Flow | -$5.5M+8.1% | -$4.7M+22.5% | -$5.8M+26.2% | -$5.7M-1619.5% | -$6.0M+8.5% | -$6.1M+5.2% | -$7.9M-7.9% | $375K+106.6% |
| Investing Cash Flow | $0-100.0% | $0+100.0% | -$9K+84.2% | $9.3M+7855.8% | $1.5M+448.1% | -$11.4M-942.6% | -$57K+50.4% | -$120K-31.9% |
| Financing Cash Flow | $2.9M+20650.0% | $477K | -$553K-103.9% | $2.1M+908.9% | $14K-95.6% | $0-100.0% | $14.3M+4220.2% | -$257K-144.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CLSD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'25 | Q4'2410-Q | Q3'2410-Q | Q2'2410-Q | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0%0.0pp | 100.0%0.0pp | 89.4%-10.6pp | 51.3% | 100.0%+16.5pp | 100.0%+20.9pp | 100.0% | N/A |
| Operating Margin | -3502.5% | -725.2% | -223.4% | -2336.3% | -571.7% | -8433.3% | -3569.1% | -45.9% |
| Net Margin | -2971.1% | -913.6% | -352.9% | -2387.6% | -740.7% | -8438.9% | -5114.4% | -76.1% |
| Return on Assets | -51.3%-24.9pp | -29.3%-6.9pp | -41.8%-12.5pp | -29.1%-14.9pp | -26.4%+0.6pp | -22.4%+0.9pp | -29.3%-8.5pp | -14.2%+4.6pp |
| Current Ratio | 2.98-1.5x | 3.87-1.2x | 3.19-2.9x | 4.440.0x | 4.49-0.8x | 5.07-1.8x | 6.07-2.5x | 4.42-4.1x |
| Asset Turnover | 0.020.0x | 0.030.0x | 0.12+0.1x | 0.01-0.2x | 0.040.0x | 0.000.0x | 0.010.0x | 0.19+0.2x |
| FCF Margin | -2726.4% | -961.2% | -250.6% | -1862.1% | -574.8% | -6781.1% | -3438.3% | 5.9% |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$38.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Clearside Biomedical, Inc. CLSD | FY2024 | $1.7M | -$34.4M | N/A | $2.1M | 43/100 |
| Tenax Therapeutics, Inc. TENX | FY2025 | $0 | -$52.6M | N/A | $70.0M | — |
| Neuphoria Therapeutics Inc. NEUP | FY2026 | $1.2M | -$13.5M | N/A | $18.2M | 48/100 |
| Dare Bioscience, Inc. DARE | FY2025 | $1.0M | -$13.4M | N/A | $15.2M | 61/100 |
| Allarity Therapeutics, Inc. ALLR | FY2025 | $320K | -$11.2M | N/A | $15.8M | — |
| REVIVA PHARMA HLDGS INC RVPH | FY2025 | N/A | -$19.9M | N/A | $10.2M | — |
Where Clearside Biomedical, Inc. Ranks
Frequently Asked Questions
What is Clearside Biomedical, Inc.'s annual revenue?
Clearside Biomedical, Inc. (CLSD) reported $1.7M in total revenue for fiscal year 2024. This represents a -79.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Clearside Biomedical, Inc.'s revenue growing?
Clearside Biomedical, Inc. (CLSD) revenue declined by 79.8% year-over-year, from $8.2M to $1.7M in fiscal year 2024.
Is Clearside Biomedical, Inc. profitable?
No, Clearside Biomedical, Inc. (CLSD) reported a net income of -$34.4M in fiscal year 2024.
What is Clearside Biomedical, Inc.'s EBITDA?
Clearside Biomedical, Inc. (CLSD) had EBITDA of -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Clearside Biomedical, Inc.'s gross margin?
Clearside Biomedical, Inc. (CLSD) had a gross margin of 91.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Clearside Biomedical, Inc.'s free cash flow?
Clearside Biomedical, Inc. (CLSD) recorded an outflow of $25.7M in free cash flow during fiscal year 2024. This represents a -28.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Clearside Biomedical, Inc.'s operating cash flow?
Clearside Biomedical, Inc. (CLSD) recorded an outflow of $24.7M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Clearside Biomedical, Inc.'s total assets?
Clearside Biomedical, Inc. (CLSD) had $25.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Clearside Biomedical, Inc.'s capital expenditures?
Clearside Biomedical, Inc. (CLSD) invested $977K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Clearside Biomedical, Inc. spend on research and development?
Clearside Biomedical, Inc. (CLSD) invested $18.6M in research and development during fiscal year 2024.
What is Clearside Biomedical, Inc.'s current ratio?
Clearside Biomedical, Inc. (CLSD) had a current ratio of 4.44 as of fiscal year 2024, which is generally considered healthy.
What is Clearside Biomedical, Inc.'s return on assets (ROA)?
Clearside Biomedical, Inc. (CLSD) had a return on assets of -136.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is Clearside Biomedical, Inc.'s debt-to-equity ratio negative or not reported?
Clearside Biomedical, Inc. (CLSD) has negative shareholder equity of -$38.9M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Clearside Biomedical, Inc.'s Altman Z-Score?
Clearside Biomedical, Inc. (CLSD) has an Altman Z-Score of -22.72, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Clearside Biomedical, Inc.'s Piotroski F-Score?
Clearside Biomedical, Inc. (CLSD) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Clearside Biomedical, Inc.'s earnings high quality?
Clearside Biomedical, Inc. (CLSD) reported a net loss of $34.4M while operations used $24.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Clearside Biomedical, Inc.?
Clearside Biomedical, Inc. (CLSD) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.